A novel quantitative flow cytometric method for measuring glucocorticoid receptor (GR) in cell lines: Correlation with the biochemical determination of GR

Journal URL: http://www.sciencedirect.com/science/journal/0022175

Solubility of glucose in mixtures containing 2-methyl-2- butanol, dimethyl sulfoxide, acids, esters, and water

Solubility measurements of glucose in a variety of binary, ternary, and multicomponent mixtures containing 2-methyl-2- butanol, dimethyl sulfoxide, acids, esters, and water at different temperatures are presented. The solubilities of crystalline beta-glucose, amorphous beta-glucose, and amorphous beta-glucose in 2-methyl-2-butanol at 60 degreesC have also been measured. The results show that the solubilities of the amorphous forms in 2-methyl-2-butanol are higher than that of the corresponding crystalline form. The presence of dimethyl sulfoxide significantly increases glucose solubility in 2- methyl-2-butanol. Finally, the presence of glucose ester increases glucose solubility in 2-methyl-2-butanol, while the presence of fatty acid has the opposite effect

Prothymosin α and Its C-Terminal Immunoreactive Decapeptide Show no Evidence of Acute Toxicity: A Preliminary in Silico, in Vitro and in Vivo Investigation.

BACKGROUND: Members of the α-thymosin family have long been studied for their immunostimulating properties. Among them, the danger-associated molecular patterns (DAMPs) prothymosin α (proTα) and its C-terminal decapeptide proTα(100-109) have been shown to act as immunomodulators in vitro, due to their ability to promote T helper type 1 (Th1) responses. Recently, we verified these findings in vivo, showing that both proTα and proTα(100-109) enhance antitumor-reactive T cell-mediated responses. METHODS: In view of the eventual use of proTα and proTα(100-109) in humans, we investigated their safety profile in silico, in human leukocytes and cancer cells lines in vitro, and in immunocompetent mice in vivo, in comparison to the proTα derivative thymosin alpha 1 (Τα1), a 28-mer peptide extensively studied for its safety in clinical trials. RESULTS: In silico prediction via computational tools showed that all three peptide sequences likely are non-toxic or do not induce allergic regions. In vitro, proTα, proTα(100-109) and Tα1 did not affect the viability of human cancer cell lines and healthy donor-derived leukocytes, did not promote apoptosis or alter cell cycle distribution. Furthermore, mice injected with proTα, proTα(100-109) and Tα1 at doses equivalent to the suggested dose regimen of Tα1 in humans, did not show signs of acute toxicity, whereas proTα and proTα(100-109) increased the levels of proinflammatory and Th1-type cytokines in their peripheral blood. CONCLUSION: Our preliminary findings suggest that proTα and proTα(100-109), even at high concentrations, are non-toxic in vitro and in an acute toxicity model in vivo; moreover, we show that the two peptides retain their immunomodulatory properties in vivo and, eventually, could be considered for therapeutic use in humans